176975-26-1

Basic information

• Product Name: Izonsteride
• Synonyms: Izonsteride;(4aR,10bR)-8-(4-Ethylbenzothiazol-2-ylsulfanyl)-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one;(4aR,10bR)-8-[(4-Ethyl-2-benzothiazolyl)thio]-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[f]quinolin-3(2H)-one
• CAS NO: 176975-26-1
• Molecular Formula: C24H26N2OS2
• Molecular Weight: 422.60604
• Mol File: 176975-26-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 608.6°C at 760 mmHg
• Flash Point: 321.9°C
• Appearance: /
• Density: 1.29g/cm³
• Vapor Pressure: 9.33E-15mmHg at 25°C
• Refractive Index: 1.686
• CAS DataBase Reference: Izonsteride(CAS DataBase Reference)
• NIST Chemistry Reference: Izonsteride(176975-26-1)
• EPA Substance Registry System: Izonsteride(176975-26-1)

Safety Data

• Hazardous Substances Data: 176975-26-1(Hazardous Substances Data)

Usage

Uses

Treatment of prostate cancer (inhibits human type I and II isoforms of 5 -reductase) .

InChI:InChI=1/C24H26N2OS2/c1-4-15-6-5-7-19-22(15)25-23(29-19)28-17-9-10-18-16(14-17)8-11-20-24(18,2)13-12-21(27)26(20)3/h5-7,9-10,14,20H,4,8,11-13H2,1-3H3/t20-,24-/m1/s1

Upstream product

• 176976-44-6 2-chloro-4-ethyl-benzothiazole 
• 176976-31-1 (+)-(4aR)-(10bR)-4-methyl-8-mercapto-10b-methyl-1,2,3,4,4a,-5,6,10b-octahydrobenzo[f]quinolin-3-one 
• 1634-04-4 tert-butyl methyl ether 
• 64741-01-1 m-chloroperoxybenzoic acid 

Relevant articles and documents

Process for the preparation of benzo[f]quinolinone derivatives and intermediates

The present invention provides a novel process for preparing benzo(f)quinolinones of the formula I wherein R1 represents: 2-nitrophenyl, 4-nitrophenyl, 2-cyanophenyl, 4-cyanophenyl, 2-nitronaphthyl, 4-nitronaphthyl, 2-cyanonaphthyl, 4-cyanonaphthyl, 2-quinolinyl, 4-quinolinyl, 7-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl, 8-isoquinolinyl, 2-quinoxalinyl, 2-benzothiazolyl, 3-1H-indazolyl, 2-benzoxazolyl, 3-1,2-benzoisothiazolyl, 2-pyridinyl, 4-pyridinyl, 2-pyrazinyl, 2-naphtho[2,3-d]thiazolyl, 2-naphtho[1,2-d]thiazolyl, 9-anthryl, 2-thiazolyl, 2-benzimidazolyl, 1-benz[g]isoquinolinyl, 8-benz[g]isoquinolinyl, 5-1H-tetrazolyl, 2-quinazolinyl, 2-thiazolo[4,5-b]pyridinyl, 4-10H-pyridazino[3,2-b]-2-quinazolinyl, 2-1,4-benzodioxinyl, 2-triazine, 2-benzoxazine, 4-benzoxazine, 2-purine or 8-purine; wherein the above R1 groups are unsubstituted or substituted; and the intermediates of the formulae A,B,C and D.

Method of preventing prostatic cancer development

A series of benzoquinolin-3-ones are pharmaceuticals effective in preventing the development of prostatic cancer, or preventing or treating the metastasis to bone of prostatic cancer.

Process for preparation of benzo[f]quinolinones

A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5α-reductase and their preparation is disclosed.